AT Bancorp boosted its position in shares of Alexion Pharmaceuticals (NASDAQ:ALXN) by 5.8% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 14,449 shares of the biopharmaceutical company’s stock after buying an additional 792 shares during the quarter. AT Bancorp’s holdings in Alexion Pharmaceuticals were worth $1,611,000 at the end of the most recent quarter.
Other hedge funds have also recently made changes to their positions in the company. Delpha Capital Management LLC purchased a new stake in shares of Alexion Pharmaceuticals during the fourth quarter valued at $102,000. CNB Bank purchased a new stake in shares of Alexion Pharmaceuticals during the fourth quarter valued at $150,000. Financial Gravity Companies Inc. lifted its holdings in shares of Alexion Pharmaceuticals by 152.0% during the first quarter. Financial Gravity Companies Inc. now owns 1,845 shares of the biopharmaceutical company’s stock valued at $211,000 after purchasing an additional 1,113 shares during the last quarter. Dupont Capital Management Corp purchased a new stake in shares of Alexion Pharmaceuticals during the first quarter valued at $220,000. Finally, Lourd Capital LLC purchased a new stake in shares of Alexion Pharmaceuticals during the fourth quarter valued at $221,000. 95.67% of the stock is owned by institutional investors and hedge funds.
Shares of Alexion Pharmaceuticals opened at $121.15 on Friday, MarketBeat.com reports. The stock has a market capitalization of $27.04 billion, a P/E ratio of 23.48, a price-to-earnings-growth ratio of 1.10 and a beta of 1.11. The company has a debt-to-equity ratio of 0.33, a current ratio of 3.35 and a quick ratio of 2.86. Alexion Pharmaceuticals has a 1 year low of $120.20 and a 1 year high of $121.73.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings data on Thursday, April 26th. The biopharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.50 by $0.18. Alexion Pharmaceuticals had a return on equity of 13.70% and a net margin of 14.46%. The firm had revenue of $930.90 million during the quarter, compared to the consensus estimate of $920.50 million. During the same period in the prior year, the business earned $1.38 EPS. The business’s revenue for the quarter was up 7.0% on a year-over-year basis. research analysts forecast that Alexion Pharmaceuticals will post 6.28 earnings per share for the current year.
In other Alexion Pharmaceuticals news, SVP Heidi L. Wagner sold 698 shares of the company’s stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $119.35, for a total value of $83,306.30. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Christopher J. Coughlin bought 10,000 shares of the company’s stock in a transaction on Monday, April 30th. The stock was purchased at an average cost of $120.79 per share, for a total transaction of $1,207,900.00. Following the completion of the transaction, the director now owns 26,333 shares in the company, valued at $3,180,763.07. The disclosure for this purchase can be found here. Corporate insiders own 4.35% of the company’s stock.
ALXN has been the subject of several analyst reports. Nomura upped their target price on Alexion Pharmaceuticals to $165.00 and gave the company a “buy” rating in a report on Thursday, April 12th. BidaskClub downgraded Alexion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Tuesday, March 27th. Zacks Investment Research downgraded Alexion Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, February 14th. Credit Suisse Group reaffirmed an “outperform” rating and set a $147.00 target price on shares of Alexion Pharmaceuticals in a report on Thursday, January 18th. Finally, SunTrust Banks set a $172.00 target price on Alexion Pharmaceuticals and gave the company a “buy” rating in a report on Monday, February 12th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and twenty have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $155.50.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.
Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals (NASDAQ:ALXN).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.